Autopsy report · NCT01219907
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Cause of deathNo reason given
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Conditions
- HER2-positive Breast Cancer; Male Breast Cancer; Stage IV Breast Cancer
- Interventions
- HER-2/neu peptide vaccine; cyclophosphamide; ex vivo-expanded HER2-specific T cells; laboratory biomarker analysis; flow cytometry; immunoenzyme technique
- Participants
- 0
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.